Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12 372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey

Blood Cancer Journal

Volumn 7, Issue 10, 2017, Pages

  Landgren, O ^a   Graubard, B I ^b   Kumar, S ^c   Kyle, R A ^c   Katzmann, J A ^d   Murata, K ^a   Costello, R ^b   Dispenzieri, A ^c   Caporaso, N ^b   Mailankody, S ^a   Korde, N ^a   Hultcrantz, M ^a   Therneau, T M ^c   Larson, D R ^c   Cerhan, J R ^c   Rajkumar, S V ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; CHILD; FEMALE; HUMAN; MALE; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUTRITION; PATHOLOGY; PREVALENCE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NUTRITION SURVEYS; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 85040467300     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2017.97     Document Type: Article

References (21)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: Cancer J Clin 2017; 67: 7–30.
2. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412–5417.
3. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010; 116: 5501–5506.
4. National Cancer Institute. SEER incidence and US death rates, age-adjusted and age-specific rates, by race and sex. Available at: http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section = 18&page = sect_18_table.06.html accessed 2 May 2009.
5. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107: 904–906.
6. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007; 82: 1468–1473.
7. Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the national health and nutritional examination survey. Leukemia 2014; 28: 1537–1542.
8. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. [erratum appears in Am J Med 1998; 105(4): 362]. Am J Med 1998; 104: 439–444.
9. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, patho-genesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 2012; 26: 609–614.
10. Ezzati TM, Massey JT, Waksberg J, Chu A, Maurer KR. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat 2 1992; 1–35.
11. Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB et al. The National Health and Nutrition Examination Survey: sample design, 1999–2006. Vital Health Stat 2 2012; 1–39.
12. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–1369.
13. Korn EL, Graubard BI. Analysis of Health Survey. Wiley: New York, NY, 1999.
14. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8: 551–561.
15. Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance (MGUS) among African-American and Caucasian women. Blood 2010; 116: 1056–1059.
16. Baris D, Brown LM, Silverman DT, Hayes R, Hoover RN, Swanson GM et al. Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health 2000; 90: 1277–1281.
17. Boffetta P, Stellman SD, Garfinkel L. A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Int J Cancer 1989; 43: 554–559.
18. Koessel SL, Theis MK, Vaughan TL, Koepsell TD, Weiss NS, Greenberg RS et al. Socioeconomic status and the incidence of multiple myeloma. Epidemiology 1996; 7: 4–8.
19. Blair CK, Cerhan JR, Folsom AR, Ross JA. Anthropometric characteristics and risk of multiple myeloma. Epidemiology 2005; 16: 691–694.
20. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–578.
21. Britton JA, Khan AE, Rohrmann S, Becker N, Linseisen J, Nieters A et al. Anthro-pometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition EPIC. Haematologica 2008; 93: 1666–1677.